Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →Indications & Uses
Met is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Metformin immediate release tablet: the dose of Metformin Hydrochloride must be individualized based on how well it controls blood sugar and how well it is tolerated, and the maximum recommended daily doses should not be exceeded. For adults, the usual starting dose of Metformin is 500 mg twice a day or 850 mg once a day, taken with meals. The dose can then be increased in steps of 500 mg every week or 850 mg every 2 weeks, up to a total of 2000 mg a day, taken in divided doses. Patients who need additional glycemic control may be given Glucomin up to a maximum daily dose of 2550 mg a day. Doses above 2000 mg a day may be tolerated better if split into three doses a day taken with meals. For children, the usual starting dose of Metformin is 500 mg twice a day, taken with meals, and the dose can be increased in steps of 500 mg every week up to a maximum of 2000 mg a day, given in divided doses. Metformin extended release tablet: the Metformin XR tablet should be swallowed whole and should never be crushed, cut or chewed. For adults, the usual starting dose of Metformin XR is 500 mg once a day, taken with the evening meal. The dose should be increased in steps of 500 mg every week, up to a maximum of 2000 mg once a day taken with the evening meal, or alternatively increased to 1000 mg twice a day taken with meals. A patient who is already taking Metformin immediate release tablets may be switched to Metformin extended release tablets, up to the maximum recommended daily dose. Metformin extended release tablets have not been studied in children. For patients with impaired kidney function, Metformin should not be used if the eGFR is below 30 mL/min/1.73 m2. The risks and benefits of continuing treatment should be assessed if the eGFR falls below 45 mL/min/1.73 m2.
Side Effects
Blood and lymphatic system disorders: Not known: Hemolytic anemia. Metabolism and nutrition disorders: Very rare: Lactic acidosis. Long-term use of metformin can lower vitamin B12 absorption and reduce its serum levels; this should be considered if a patient develops megaloblastic anemia. Cases of peripheral neuropathy in patients with vitamin B12 deficiency have been reported after the medicine reached the market (frequency not known). Nervous system disorders: Common: Taste disturbance. Not known: Encephalopathy. Gastrointestinal disorders: Very common: Gastrointestinal effects such as nausea, vomiting, diarrhea, abdominal pain, and loss of appetite. These effects occur most often when treatment is first started and usually go away on their own. To help prevent them, metformin should be taken in 2 or 3 doses a day, during or after meals, and raising the dose slowly can also help the stomach tolerate it better. Hepatobiliary disorders: Very rare: Isolated reports of abnormal liver function tests or hepatitis that resolved once metformin was stopped. Skin and subcutaneous tissue disorders: Very rare: Skin reactions such as redness, itching, and hives.
Cautions & Contraindications
Warnings & Precautions
Glunor OD is largely cleared from the body by the kidneys, and the risk of Glunor OD buildup and lactic acidosis rises as kidney function declines. Glunor OD may lower vitamin B12 levels, and it also raises the risk of hypoglycaemia when used together with insulin or an insulin secretagogue. Because Glunor OD is excreted by the kidneys, regular monitoring of renal function is advised for all diabetic patients. Glunor OD therapy should be stopped 2 to 3 days before surgery and before clinical investigations such as intravenous urography and intravenous angiography, and should only be restarted once renal function has been confirmed to be normal or has recovered. Glunor OD is not advised in conditions that may cause dehydration or in patients with serious infections or trauma. Patients on continuous Glunor OD therapy should have their vitamin B12 levels checked annually, since there have been reports of reduced vitamin B12 absorption. When Glunor OD is taken together with a sulphonylurea, blood glucose should be monitored, as the combination may cause hypoglycaemia. Stabilizing diabetic patients on both Glunor OD and insulin should be done in a hospital setting, given the risk of hypoglycaemia until the right balance between the two medicines has been established. Reduced renal clearance of Glunor OD has been reported during cimetidine therapy, so a dose reduction should be considered. As with a number of medicines, an interaction between Glunor OD and anticoagulants is possible, and the anticoagulant dose may need to be adjusted.
Contraindications
Hypersensitivity to the active substance or to any of the excipients. Any type of acute metabolic acidosis, including lactic acidosis and diabetic ketoacidosis. Severe renal failure, with GFR below 30 mL/min. Acute conditions that could affect kidney function, such as dehydration, severe infection, or shock. Any acute or chronic disease that may cause tissue hypoxia, including cardiac or respiratory failure, a recent heart attack, or shock. Hepatic insufficiency, acute alcohol intoxication, and alcoholism.